Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Global Stock · Morgan Stanley

Global Endurance Portfolio Class C (MSJCX)

Ticker MSJCX · · Holdings as of Jun 30, 2026

Expense ratio
2.1%$210/yr per $10k
5-yr return
−4.4%annualized
1-yr return
+22.3%as of Dec 2025
Net assets
$16.2Mall share classes
Holdings
31

Bottom line

Is MSJCX a good fund? The bottom line

MSJCX is the Class C share class of Global Endurance Portfolio, an actively managed global stock mutual fund from Morgan Stanley.

Annual fees run 2.1% — about $210 a year on every $10,000 invested, more expensive than 98% of global stock funds we track.

It returned +22.3% over one year, −4.4% a year over five years (as of Dec 31, 2025, per its prospectus).

With $16.2 million in net assets and 31 holdings, its largest position is Victoria PLC (19.0%) and the top 10 make up 61.6% of the portfolio.

What stands out

  • No front-end sales load

What to watch

  • Expensive for its category (2.1%)
  • 5-year return in the bottom quarter of its category
  • Concentrated: top 10 holdings are 61.6% of assets
  • 12b-1 marketing fee of 1% a year
  • Small fund ($16.2 million) — small funds are likelier to close

Updated Nov 19, 2026

What MSJCX invests in

The Global Endurance Portfolio (the Fund) seeks long-term capital appreciation.

Under normal market conditions, the Adviser seeks to achieve the Funds investment objective by investing primarily in equity securities of established and emerging companies located throughout the world, with capitalizations within the range of companies included in the MSCI All Country World Index. The Adviser emphasizes a bottom-up stock selection process, seeking attractive investments on an individual company basis. In selecting securities for investment, the Adviser seeks to invest in companies with strong name recognition and sustainable competitive advantages. The Adviser typically favors companies with rising returns on invested capital, above-average business visibility, strong free cash flow generation and an attractive risk/reward. The Adviser typically focuses a significant portion of the Funds investments in a limited number of issuers, which may be in the same industry…

From the fund's prospectus (filed Apr 30, 2026).

MSJCX performance

Average annual total returns
1 yr5 yr10 yr
MSJCX+22.3%−4.4%—
Global Stock median+15.2%+7.6%+9.5%

Source: Fund prospectus, as of Dec 31, 2025

Full MSJCX performance history →

What MSJCX costs

On a $10,000 investment, MSJCX's 2.1% expense ratio costs about $210 a year. The prospectus estimates $3,238 in total costs over 10 years (assuming 5% annual returns). The median global stock fund charges 0.95%.

See the full MSJCX fee table →

MSJCX top 10 holdings

#Holding% of fund
1Victoria PLC19.05%
2Roivant Sciences Ltd7.26%
3Arbutus Biopharma Corp5.50%
4Immunovant Inc4.86%
5QXO Inc4.84%
6Floor & Decor Holdings Inc4.83%
7Teleflex Inc4.11%
8Royalty Pharma PLC3.82%
9DraftKings Inc3.70%
10Calumet Inc3.63%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 61.6% of the fund. See all top 25 holdings and asset mix →

Alternatives to MSJCX

More funds like MSJCX →

MSJCX FAQ

What is the expense ratio of MSJCX?
MSJCX's expense ratio is 2.1%, which works out to about $210 a year for every $10,000 invested. The prospectus estimates total costs of $3,238 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is MSJCX a good investment?
It depends on your goals, but the data points to: no front-end sales load; expensive for its category (2.1%); 5-year return in the bottom quarter of its category; concentrated: top 10 holdings are 61.6% of assets; 12b-1 marketing fee of 1% a year; small fund ($16.2 million) — small funds are likelier to close. This is general information, not personalized advice.
What does MSJCX hold?
MSJCX's largest holdings are Victoria PLC (19.0%), Roivant Sciences Ltd (7.3%), Arbutus Biopharma Corp (5.5%), Immunovant Inc (4.9%), QXO Inc (4.8%). It holds 31 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is MSJCX's 5-year return?
MSJCX returned −4.4% a year over the five years ending Dec 31, 2025. Past performance does not guarantee future results.
Does MSJCX have a sales load?
No. MSJCX has no front-end sales charge. It may charge a deferred sales charge of up to 1% if sold early.
Who manages MSJCX?
MSJCX is offered by Morgan Stanley through Morgan Stanley Institutional Fund Inc.